ZielBio, Inc., an early-stage biotechnology company that identifies novel high value disease targets and develops therapeutic interventions to improve patient outcomes, has closed a $25.1 million Series A financing round. The round is led by Morningside Venture Investments and Partners Innovation Fund (PIF). ZielBio’s lead candidate ZB131 is a proprietary humanized monoclonal … [Read more...] about ZielBio Closes $25.1 Million Series A Financing to Enable Development of Monoclonal Antibody ZB131